A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-label study evaluated the safety and antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharman, Jeffrey P., Wheler, Jennifer J., Einhorn, Lawrence, Dowlati, Afshin, Shapiro, Geoffrey I., Hilton, John, Burke, John M., Siddiqi, Tanya, Whiting, Nancy, Jalal, Shadia I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647393/
https://www.ncbi.nlm.nih.gov/pubmed/30993587
http://dx.doi.org/10.1007/s10637-019-00768-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647393/
https://www.ncbi.nlm.nih.gov/pubmed/30993587
http://dx.doi.org/10.1007/s10637-019-00768-6

Ejemplares similares